Skip to main content

Table 4 Most frequent potential drug-drug exposures. The classification of a drug-drug exposure was determined by the prescription information for the brand-name drugs

From: Frequency and clinical relevance of potential cytochrome P450 drug interactions in a psychiatric patient population – an analysis based on German insurance claims data

Potential drug-drug exposure

Frequency

Events per 100 person-years (Poisson exact 95 %–CI)

Number of patients with at least one DDE (%)

Clinical relevance of a potential interaction (as per prescribing information)

diazepam & omeprazole

52

1.00 (0.74–1.31)

17 (1.39)

Omeprazole may increase systemic exposure to diazepam [31]

doxepin & venlafaxine

54

1.03 (0.78–1.35)

15 (1.23)

not mentioned

doxepin & paroxetine

44

0.84 (0.61–1.13)

13 (1.06)

not mentioned

amitriptyline & omeprazole

58

1.11 (0.84–1.44)

12 (0.98)

not mentioned

doxepin & tramadol

51

0.98 (0.73–1.28)

11 (0.90)

Tramadol may increase the potential of seizures related to tricyclic antidepressants. Serotonin syndrome may occur [32] [unclear if due to CYP interactions]

amitriptyline & paroxetine

29

0.56 (0.37–0.80)

9 (0.74)

Patients taking SSRIs should only be treated with amitriptyline with particular caution [33] [reason not given]

amitriptyline & esomeprazole

31

0.59 (0.40–0.84)

8 (0.66)

not mentioned

doxepin & risperidone

95

1.82 (1.47–2.22)

8 (0.66)

Mutual reinforcement of the central depressant effect [34]

fluoxetine & omeprazole

11

0.21 (0.11–0.38)

8 (0.66)

not mentioned

doxepin & duloxetine

22

0.42 (0.26–0.64)

7 (0.57)

not mentioned

    

Sum

1393

26.72 (25.34–28.16)

330